Literature DB >> 20485318

Dealing with the evidence dilemma in genomics and personalized medicine.

M J Khoury1.   

Abstract

In this commentary, I discuss how the promise of genomics and personalized medicine (GPM) is currently not matched by the evidence that supports its use in clinical practice. The mismatch between expectations and reality can be addressed by placing greater emphasis on multidisciplinary translation research and by stakeholder-driven collaboration that uses such research to address various and occasionally competing factors affecting the integration of genomic discoveries into clinical practice.

Mesh:

Year:  2010        PMID: 20485318     DOI: 10.1038/clpt.2010.4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

1.  Multilevel research and the challenges of implementing genomic medicine.

Authors:  Muin J Khoury; Ralph J Coates; Mary L Fennell; Russell E Glasgow; Maren T Scheuner; Sheri D Schully; Marc S Williams; Steven B Clauser
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

2.  Assessing the integration of genomic medicine in genetic counseling training programs.

Authors:  Jessica Profato; Erynn S Gordon; Shannan Dixon; Andrea Kwan
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

3.  Public attitudes towards genomic risk profiling as a component of routine population screening.

Authors:  S G Nicholls; B J Wilson; S M Craigie; H Etchegary; D Castle; J C Carroll; B K Potter; L Lemyre; J Little
Journal:  Genome       Date:  2013-08-31       Impact factor: 2.166

4.  Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.

Authors:  D S Dhanda; G F Guzauskas; J J Carlson; A Basu; D L Veenstra
Journal:  Clin Pharmacol Ther       Date:  2017-07-10       Impact factor: 6.875

5.  Personalised medicine: a critique on the future of health care.

Authors:  Jacqueline Savard
Journal:  J Bioeth Inq       Date:  2013-03-21       Impact factor: 1.352

6.  Concerns about unintended negative consequences of informing the public about multifactorial risks may be premature for young adult smokers.

Authors:  Erika A Waters; Caroline Kincaid; Annette R Kaufman; Michelle L Stock; Laurel M Peterson; Nicole L Muscanell; Rosanna E Guadagno
Journal:  Br J Health Psychol       Date:  2013-10-01

7.  Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.

Authors:  Michael J Sorich; Andrew Rowland; Michael D Wiese
Journal:  Ther Adv Drug Saf       Date:  2014-04

8.  Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.

Authors:  Jason L Vassy; Sojeong Chun; Sanjay Advani; Sophie A Ludin; Jason G Smith; Elaine C Alligood
Journal:  Clin Pharmacol Ther       Date:  2018-10-18       Impact factor: 6.875

9.  The Population Health OutcomEs aNd Information EXchange (PHOENIX) Program - A Transformative Approach to Reduce the Burden of Chronic Disease.

Authors:  Steven J Korzeniewski; Carla Bezold; Jason T Carbone; Shooshan Danagoulian; Bethany Foster; Dawn Misra; Maher M El-Masri; Dongxiao Zhu; Robert Welch; Lauren Meloche; Alex B Hill; Phillip Levy
Journal:  Online J Public Health Inform       Date:  2020-05-16

10.  The emergence of translational epidemiology: from scientific discovery to population health impact.

Authors:  Muin J Khoury; Marta Gwinn; John P A Ioannidis
Journal:  Am J Epidemiol       Date:  2010-08-05       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.